These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 26132671)

  • 1. Nocebo effects in the treatment of major depression: results from an individual study participant-level meta-analysis of the placebo arm of duloxetine clinical trials.
    Dodd S; Schacht A; Kelin K; Dueñas H; Reed VA; Williams LJ; Quirk FH; Malhi GS; Berk M
    J Clin Psychiatry; 2015 Jun; 76(6):702-11. PubMed ID: 26132671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials.
    Nelson JC
    Depress Anxiety; 2010; 27(1):12-8. PubMed ID: 20013987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD).
    Baldwin DS; Loft H; Dragheim M
    Eur Neuropsychopharmacol; 2012 Jul; 22(7):482-91. PubMed ID: 22209361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo.
    Robinson M; Oakes TM; Raskin J; Liu P; Shoemaker S; Nelson JC
    Am J Geriatr Psychiatry; 2014 Jan; 22(1):34-45. PubMed ID: 24314888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder.
    Arnold LM; Hudson JI; Wang F; Wohlreich MM; Prakash A; Kajdasz DK; Chappell AS
    Clin J Pain; 2009; 25(6):461-8. PubMed ID: 19542792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients.
    Stewart DE; Wohlreich MM; Mallinckrodt CH; Watkin JG; Kornstein SG
    J Affect Disord; 2006 Aug; 94(1-3):183-9. PubMed ID: 16780958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and characteristics of the nocebo response from meta-analyses of the placebo arms of clinical trials of olanzapine for bipolar disorder.
    Dodd S; Walker AJ; Brnabic AJM; Hong N; Burns A; Berk M
    Bipolar Disord; 2019 Mar; 21(2):142-150. PubMed ID: 29926533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials.
    Hudson JI; Wohlreich MM; Kajdasz DK; Mallinckrodt CH; Watkin JG; Martynov OV
    Hum Psychopharmacol; 2005 Jul; 20(5):327-41. PubMed ID: 15912562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
    Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Marangell LB
    Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
    Greist J; McNamara RK; Mallinckrodt CH; Rayamajhi JN; Raskin J
    Clin Ther; 2004 Sep; 26(9):1446-55. PubMed ID: 15531007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
    Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ
    Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety of duloxetine during open-label compassionate use treatment of patients who completed previous duloxetine clinical trials.
    Pangallo BA; Zhang Q; Desaiah D; Perahia DG; Detke MJ; Kennedy SH
    Curr Med Res Opin; 2010 Nov; 26(11):2643-51. PubMed ID: 20932222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol.
    Oakes TM; Myers AL; Marangell LB; Ahl J; Prakash A; Thase ME; Kornstein SG
    Hum Psychopharmacol; 2012 Jan; 27(1):47-56. PubMed ID: 22241678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies.
    Brannan SK; Mallinckrodt CH; Detke MJ; Watkin JG; Tollefson GD
    J Psychiatr Res; 2005 Mar; 39(2):161-72. PubMed ID: 15589564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.